ReviewDrugs & aging2005
Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.
Review in Drugs & aging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00438048 (Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva
Who cites it
15 citing papers in PubMed, 63 citations in OpenAlex.
- Comparison of transcutaneous electrical nerve stimulation and interferential therapy for salivary stimulation in postmenopausal women: a pilot study.Scientific reports · 2026Trial
- An ex vivo salivary lubrication system to mimic xerostomic conditions and to predict the lubricating properties of xerostomia relieving agents.Scientific reports · 2018Trial
- Role of hormone replacement therapy in relieving oral dryness symptoms in postmenopausal women: a case control study.BMC oral health · 2021Article
- An Update on the Lived Experience of Dry Mouth in Sjögren's Syndrome Patients.Frontiers in oral health · 2021Review
- Next Generation Salivary Lubrication Enhancer Derived from Recombinant Supercharged Polypeptides for Xerostomia.ACS applied materials & interfaces · 2020Article
- Potentially inappropriate anticholinergic drug prescriptions for patients with Sjögren's syndrome.Journal of translational autoimmunity · 2019Article
- The lived experience of Sjögren's Syndrome.BMC oral health · 2016Article
- Frequency and risk factors associated with dry eye in patients attending a tertiary care ophthalmology center in Mexico City.Clinical ophthalmology (Auckland, N.Z.) · 2016Article
- The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.Clinical reviews in allergy & immunology · 2015Review
- Visits to physicians for oral health-related complaints in Ontario, Canada.Canadian journal of public health = Revue canadienne de sante publique · 2015Article
- Sjögren's syndrome in older patients: aetiology, diagnosis and management.Drugs & aging · 2013Review
- Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly.Drugs & aging · 2008Review
- Cevimeline.Drugs · 2008Article
- Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment.Drugs & aging · 2007Review
- [Sjögren's syndrome. Current aspects from a rheumatological point of view].Zeitschrift fur Rheumatologie · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xerostomia is a common symptom in the elderly population. Studies have suggested that the underlying cause of approximately 40% of xerostomia in the elderly is Sjögren's syndrome. Although it is highly prevalent among middle-aged individuals, elderly patients account for up to 20% of Sjögren's syndrome cases. Sjögren's syndrome is a multisystem exocrinopathy characterised by dry mouth and dry eyes with wide-ranging extraglandular involvement. The exocrine manifestations of Sjögren's syndrome affect the mouth, eyes, nose, ears, skin, vagina and the entire respiratory and gastrointestinal systems. The nonexocrine involvement may include the joints, thyroid gland, liver, kidneys and the musculoskeletal, vascular and central nervous systems. Currently, the mechanism(s) of development and progression of Sjögren's syndrome is/are not clear. Inflammation and lymphocytic infiltration of the exocrine glands is a classical feature of Sjögren's syndrome. During the progression of the disease, the acinar cells of the exocrine glands are replaced by fibrosis, rendering the glands nonfunctional. Sjögren's syndrome remains one of the most underdiagnosed conditions, particularly in the elderly population, because the cardinal sicca symptoms, which are the hallmark of the disease, are frequently attributed to aging and/or medications, which consequently delays the diagnosis. This delay in diagnosis imposes significant physical, psychological and economic burdens on elderly patients. The diagnosis of Sjögren's syndrome requires evaluation of both the exocrine and nonexocrine components of the disease. Management of Sjögren's syndrome requires collaboration by the primary-care physician, rheumatologist, ophthalmologist and dentist. This article reviews current understanding of the clinical manifestations, diagnosis and treatment of Sjögren's syndrome with special emphasis on the oral component of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.